

ZENOTECH LABORATORIES LIMITED

8-2-120/112/88-89/P/2, 4th Floor, Park View Estate, Road No.2, Banjara Hills
Hyderabad - 500 034

Audited financial results for the year ended March 31, 2009


(Rs. lakhs)

		Standalone Financials				Consolidated Financials	
		Quarter ended		Year ended		Year ended	
		31/Mar/09	31/Mar/08	31/Mar/09	31/Mar/08	31/Mar/09	31/Mar/08
		Audited	Audited	Audited	Audited	Audited	Audited
1	a. Net Sales/Income from operations	64.75	66.65	602.32	823.55	602.32	823.55
	b. Other operating income	-	-	-	-	-	-
	Total income	64.75	66.65	602.32	823.55	602.32	823.55
2	Expenditure						
	a. (Increase) / decrease in stock in trade and work in progress	33.67	71.31	171.88	13.06	190.29	12.12
	b. Consumption of raw materials	(3.26)	50.82	299.04	253.52	319.86	272.82
	c. Other expenditure	99.73	103.72	411.55	367.23	411.55	367.23
	d. Employee cost	229.28	115.81	622.25	499.69	720.35	620.80
	e. Administration, selling and distribution and other expenses	189.99	66.96	384.29	246.25	406.22	314.30
	f. Product development expenses	134.42	58.44	310.47	201.28	138.10	91.31
	g. Depreciation	71.19	80.77	294.07	290.45	307.44	303.01
	h. Amortisation of miscellaneous expenditure including product development expenditure	29.85	32.97	119.41	133.41	119.74	133.41
	i. Total	784.87	580.80	2,612.96	2,004.89	2,613.55	2,115.00
3	Profit (+)/ loss (-) from operations before other income, interest and exceptional items (1 - 2)	(720.12)	(514.15)	(2,010.64)	(1,181.34)	(2,011.23)	(1,291.45)
4	Other income	154.50	145.69	515.47	216.90	462.58	216.90
5	Profit (+)/ loss (-) before interest and exceptional items (3 + 4)	(565.62)	(368.46)	(1,495.17)	(964.44)	(1,548.65)	(1,074.55)
6	Interest	46.95	66.23	201.81	270.91	207.37	279.98
7	Profit (+)/ loss (-) after interest and exceptional items (5 - 6)	(612.57)	(434.69)	(1,696.98)	(1,235.35)	(1,756.02)	(1,354.53)
8	Exceptional items	465.48	-	465.48	-	-	-
9	Profit (+)/ loss (-) from ordinary activities before tax (7+ 8)	(1,078.05)	(434.69)	(2,162.46)	(1,235.35)	(1,756.02)	(1,354.53)
10	Tax expense	1.37	230.41	4.61	234.91	4.61	234.91
11	Net profit (+)/ loss (-) from ordinary activities after tax (9 - 10)	(1,079.42)	(665.10)	(2,167.07)	(1,470.26)	(1,760.63)	(1,589.44)
12	Extraordinary item (net of tax expenses Rs. Nil)	-	-	-	-	-	17.77
13	Net profit (+)/ loss (-) for the period (11 - 12)	(1,079.42)	(665.10)	(2,167.07)	(1,470.26)	(1,760.63)	(1,607.21)
14	Paid-up equity share capital (Face value of Rs.10/- per equity share)	3,442.50	3,435.00	3,442.50	3,435.00	3,442.50	3,435.00
15	Reserves excluding revaluation reserves as per balance sheet of previous accounting year			11,641.76	11,596.98	11,641.76	11,596.98
16	Earnings per share (not annualized) (Rs.)						
	a. Before extraordinary items						
	- Basic	(3.14)	(2.16)	(6.30)	(4.78)	(4.94)	(5.22)
	- Diluted	(3.14)	(2.16)	(6.30)	(4.78)	(4.94)	(5.22)
	b. After extraordinary items						
	- Basic	(3.14)	(2.16)	(6.30)	(4.78)	(4.94)	(5.22)
	- Diluted	(3.14)	(2.16)	(6.30)	(4.78)	(4.94)	(5.22)
17	Public shareholding						
	- Number of shares	9,428,311	9,505,854	9,428,311	9,505,854	9,428,311	9,505,854
	- Percentage of shareholding	27.39%	27.67%	27.39%	27.67%	27.39%	27.67%
18	Promoter Shareholding - No. of Shares						
	a) Pledged / Encumbered						
	- No of shares	850,000		850,000		850,000	
	- Percentage of shares (as a % of the total shareholding of promoter & promoter group)	9.58%		9.58%		9.58%	
	- Percentage of shares (as a % of the total shareholding of the Company)	2.47%		2.47%		2.47%	
	b) Non-encumbered						
	- No of shares	8,019,396		8,019,396		8,019,396	
	- Percentage of shares (as a % of the total shareholding of promoter & promoter group)	16.18%		16.18%		16.18%	
	- Percentage of shares (as a % of the total shareholding of the Company)	23.29%		23.29%		23.29%	

Notes:

- The above results were approved by the Board of Directors at its meeting held on November 16, 2009
- The Company operated in one segment only - Pharmaceuticals.
- In the previous year, in terms of its shareholders resolution dated 8th November, 2007 the Company has issued 54,89,536 equity shares of Rs.10/- each to M/s. Ranbaxy Laboratories Limited at a premium of Rs. 150/- per share on preferential allotment basis on 23rd November, 2007. Out of the proceeds of Rs.8783.25 lakhs from the aforesaid issue, the Company utilised the funds for repayment of secured and unsecured loans, to meet Product development expenditure and the working capital needs of the company etc., Balance unutilised amount of Rs.3121.57 lakhs has been invested in Fixed Deposits with Banks.
- During the quarter under review, the following is the status of investor compliants : opening balance : nil; received during the quarter : nil; resolved during the quarter: nil;
- The public shareholding as mentioned at point no.17 above includes only general public. Ranbaxy Laboratories Limited's shareholding in the Company, constituting 46.85% has not been included in the above, as opinion regarding status of shareholder is awaited.
- The annual general meeting of the Company for the financial year 2007-08 is not held to adopt the audited financial statements of the Company for the said year. As such opening balances carried forward to current year's books of account are subject to the approval of the shareholders.
- Figures have been regrouped/reclassified and recast wherever necessary.

By order of the Board



Dr. Jayaram Chigurupati
Managing Director

Place: Hyderabad
Date: 16/11/2009